Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07666126

Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss

Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.

A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Recep Tayyip Erdoğan University

Rize, 53020, Turkey (Türkiye)

Location status: Recruiting

Location contact

Hatice Yemenoglu

CONTACT

[email protected]

+904642220000

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Being between 18 and 65 years of age
  • Being systemically healthy or diagnosed with hyperuricemia
  • Having at least 20 natural teeth
  • Being periodontally healthy or diagnosed with periodontitis

Exclusion criteria

  • Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
  • Smoking
  • Pregnancy or lactation
  • Having received periodontal treatment within the last 3-6 months
  • Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs
  • Presence of systemic diseases that may affect purine metabolism

Treatment and study plan

Collection of gingival crevicular fluid (GCF) and serum samples

Other

Serum and GCF samples will be collected from participants in the first session

measurement of periodontal clinical parameters

Other

Periodontal clinical parameters will be measured from participants initially

Primary outcomes

  1. Periodontal pocket depth

    Time frame: at baseline

    The distance between the gingival margin and the base of the pocket will be measured in millimeters.

  2. clinical attachment loss

    Time frame: at baseline

    The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.

Secondary outcomes

  1. Level of interleukin-1 beta

    Time frame: at baseline

    Interleukin-1 beta levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

  2. Level of interleukin-10

    Time frame: at baseline

    Interleukin-10 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

  3. Level of interleukin-18

    Time frame: at baseline

    Interleukin-18 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.

Study contacts

Contact information is provided by the study sponsor or research team.

Hatice Yemenoglu

CONTACT

[email protected]

+905052977517

Sponsors and collaborators

Lead sponsor

Recep Tayyip Erdogan University Training and Research Hospital

Other

Registry information

Official study title

Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jun 24, 2026
Registry last updated
Jun 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.